GLP-1 receptor agonists demonstrate kidney-protective effects in type 2 diabetes through anti-inflammatory, antioxidant, and natriuretic mechanisms, with the FLOW trial showing a 24% reduction in kidney and cardiovascular composite endpoints.
24% reductionin kidney/cardiovascular composite endpoint with semaglutide in the FLOW trial
What the researchers found
The FLOW trial demonstrated a 24% reduction in a composite kidney/cardiovascular endpoint with semaglutide in T2DM patients with CKD, validating GLP-1 RA kidney protection.
Why it matters
Diabetic kidney disease is a leading cause of kidney failure worldwide. GLP-1 agonists could join SGLT2 inhibitors as another class of kidney-protective diabetes medications, giving clinicians more options to slow kidney decline.
The numbers in context
Review covered evidence on albuminuria reduction, eGFR preservation, and cardiovascular risk mitigation across multiple studies.
How the study worked
Narrative review synthesizing clinical trial evidence, mechanistic studies, and preliminary FLOW trial results on GLP-1 RA kidney protective effects in type 2 diabetes with chronic kidney disease.
Who was studied
People with type 2 diabetes and chronic kidney disease
What this study cannot tell us
Review written before full FLOW trial data publication; mechanistic pathways largely from preclinical data; unclear whether kidney benefits are independent of glucose and weight effects; not all GLP-1 RAs may have equivalent kidney protection; dose adjustment needed in severe CKD.
How to read the evidence
Strong evidence based on a stopped-for-efficacy randomized trial (FLOW) plus supporting data from multiple prior studies and mechanistic research.
When this study was published
Published in 2024, anticipating the full FLOW trial results — the first dedicated kidney outcomes trial for a GLP-1 RA.
The bigger picture
The FLOW trial results position GLP-1 agonists alongside SGLT2 inhibitors and finerenone as kidney-protective agents in diabetes, potentially transforming the standard of care for diabetic kidney disease management.
Questions still open
- Is GLP-1 RA kidney protection additive to SGLT2 inhibitor benefits?
- Do all GLP-1 RAs provide similar kidney protection or is it drug-specific?
- Can GLP-1 RAs prevent kidney disease in early-stage diabetes before CKD develops?
Common questions
Can GLP-1 medications like semaglutide protect your kidneys?
How do GLP-1 medications protect the kidneys?
Read the original research
Potential kidney protective effects of glucagon-like peptide-1 receptor agonists.
Nephrology (Carlton, Vic.), 29(8), 457-469
Citation
Trevella, Philippa; Ekinci, Elif I; MacIsaac, Richard J. (2024). Potential kidney protective effects of glucagon-like peptide-1 receptor agonists.. Nephrology (Carlton, Vic.), 29(8), 457-469. https://doi.org/10.1111/nep.14336